ReviewActa oncologica (Stockholm, Sweden)2026
Tools for providing information to patients about high-tech medical resources for treatment of cancer.
Julie Gehl, Tatiana Michel, Erik Rokkones, Soleakhena Ken, Gregor Sersa, Irene Torres-Espallardo, Ester Orlandi, Laura Ridolfi, Nina Schmidt, Ingrid Kruecken and 18 more
Abstract readReview
In one paragraphReview in Acta oncologica (Stockholm, Sweden), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
28 authors.
Julie GehlDepartment of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. geh@regionsjaelland.dk.ORCID 0000-0003-3829-0210 Tatiana MichelDepartment of Luxembourg Research Clinic, Luxembourg Institute of Health, Strassen, Luxembourg.ORCID 0000-0002-0146-9236 Erik RokkonesDepartment of Surgical Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
Soleakhena KenInstitut Universitaire du Cancer de Toulouse - Oncopole Claudius Regaud, Univ Toulouse France.ORCID 0000-0001-7904-5882 Gregor SersaDepartment of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.ORCID 0000-0002-7641-5670 Irene Torres-EspallardoNuclear Medicine Department and Clinical Area of Medical Imaging, Hospital Universitario y Politécnico La Fe, Valencia, Spain.ORCID 0000-0002-4612-4629 Ester OrlandiDepartment of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.ORCID 0000-0001-6495-8574 Laura RidolfiDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola (FC), Italy.ORCID 0000-0003-1870-3380 Nina SchmidtDepartment of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark.
Ingrid KrueckenPatient & Public Involvement (PPI) Group, Luxembourg Institute of Health (LIH), Luxembourg, Luxembourg; Board of Europa Donna Luxembourg asbl, Strassen, Luxembourg; Board of Europa Donna - the European Breast Cancer Coalition, Milan, Italy; ESMO PAWG (Patient Advocates Working Group), Lugano, Switzerland.
Barbara LeonardiMyeloma Patients Europe, Carita Foundation Poland, Wrocław, Poland.
Margareta HaagSwedish Network against Cancer, President, Stockholm, Sweden; EUPATI Sweden, Board Member, Stockholm, Sweden; Member of OECI Working Group for patients, Rome, Italy.
Sandrine LavalléDepartment of Luxembourg Research Clinic, Luxembourg Institute of Health, Strassen, Luxembourg.
Colin Patrick CantwellSt. Vincents University Hospital and University College Dublin, Elm Park, Dublin, Ireland.ORCID 0000-0002-2532-9422 Alexander Jorge CortezDepartment of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland; Digital Medicine Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.ORCID 0000-0003-1284-2638 Roger Olofsson BaggeDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.ORCID 0000-0001-5795-0355 Massimiliano PetriniExperimental and Clinical Oncology of Immunotherapy and Rare Cancers, Immuno-Gene Therapy Factory, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola (FC), Italy.ORCID 0000-0002-8942-0890 Vincent BourbonneService de Radiothérapie, Institut de Cancérologie et d'Imagerie, CHU Brest, France; INSERM, LaTIM, UMR 1101, Université de Bretagne Occidental, France.ORCID 0000-0002-2631-0029 Ibrahim EdhemovićDepartment of Surgical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Faculty of Medicine Ljubljana, University of Ljubljana, Ljubljana, Slovenia.ORCID 0000-0001-8122-7896 Lisa LicitraMedical Oncology 3 Department, Fondazione IRCCS Instituto Nazionale dei Tumori, Milano, Italy; Università degli Studi di Milano, Milano, Italy.ORCID 0000-0003-0623-4118 Author study group
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
background and purposeHigh-tech medical resources play an increasingly important role in cancer diagnosis and treatment. However, accessing information about these technologies remains challenging due to their complexity and a lack of clear information pathways to obtain reliable information. This, in turn, contributes to inequalities in healthcare. Patient/material and methods: The Joint Action Network of Expertise on Cancer (JANE-2) is one of the largest networks under Europe's Beating Cancer Plan. In JANE-2, the work package on High-Tech Medical Resources comprises seven domains of rapidly evolving technologies, namely Nuclear Medicine, Radiomics, Innovative Radiotherapy, Innovative Surgery, Physical Methods of Ablation, Cell Therapies, and Ex-vivo Testing of Agents. Leaders from these domains, together with patient representatives, have authored a review of the challenges of providing patients with information about high-tech medical resources, and have proposed potential solutions.
resultsThis article describes the challenges associated with providing adequate information to patients, the resulting consequences, and potential solutions. The article also specifically describes technologies related to the seven high-tech domains that are central to cancer treatment. Patient information tools related to these technologies are provided as supplementary material to the article.
interpretationCancer diagnosis and treatment are not only becoming increasingly effective but also more complex with the adoption of novel technologies. This article discusses the challenges and potential solutions related to the availability of patient information and provides examples of patient information tools for seven key and rapidly advancing technologies.
Indexed as
NeoplasmsPatient Education as TopicEuropeHumans
Identifiers
PMID42825514
PMCPMC13635841
What OpenQuestion holds
Textmetadata
Read underepoch 390